CN Stock MarketDetailed Quotes

002437 Harbin Gloria Pharmaceuticals

Watchlist
  • 2.54
  • +0.10+4.10%
Market Closed Dec 27 15:00 CST
5.79BMarket Cap72.57P/E (TTM)

About Harbin Gloria Pharmaceuticals Company

Since its launch in 2010, the company has been adhering to the “product leading” strategy, and has enriched the company's product line through various methods such as epitaxial mergers and acquisitions, cooperative agents, independent research and development, and overseas introduction, etc., and has expanded from the narrow and single orthopedic treatment field at the beginning of the listing to the existing major treatment fields such as cardiovascular and cerebrovascular fields, skeletal muscle fields, nutritional medicine, etc., and a new pattern of multi-product-driven performance growth has gradually emerged. The company is mainly engaged in R&D, production and sales of pharmaceuticals. The company's main products include amlodipine tablets, sodium creatine phosphate for injection, ginkgo damole injections, olmesartan amlodipine tablets, edoxaban tablets, pravastatin tablets, carvastatin sodium tablets, sodium hyaluronate injections, multivitamin (12) compound vitamin (3) injections, potassium chloride sustained-release tablets, injectable potassium magnesium aspartate, sodium deoxynucleotide sodium injection (DNA), levocarnitine injection, and compound glycyrrhizinate for injection Ammonium S, cefaclor for injection, compound cefaclor capsules, calcium levofolate for injection, fluorouracil for injection, Cyclophosphamide for injection, Pingyangmycin hydrochloride for injection, silodosin capsules, etc. Corporate honors: In October 2018, Yuheng Pharmaceutical won the title of 2018 Top 100 Comprehensive Strength Industrial Enterprises in China's Chemical and Pharmaceutical Industry. In July 2018, Yuheng Pharmaceutical was listed as one of the “Top 100 Pharmaceutical Industries in China”. In June 2018, Yuheng Pharmaceutical won two awards: “2017 China's Top 100 Pharmaceutical Industry” and “2017 China Pharmaceutical Law-abiding and Honest Enterprise”. In May 2018, Yuheng Pharmaceutical won the 2018 Brand Value Assessment Enterprise Brand List, “2022 Top 100 Chinese Chemical Companies”, “Specialized and New” SMEs, “2022 Outstanding Private Enterprises in Datong City”, “2022 Outstanding Tax Contribution Award”, “Outstanding Economic Contribution Enterprise Award”, and “Outstanding Tax Contribution Enterprise Award”.

Company Profile

Short Name-A誉衡药业
Symbol-A002437
Company NameHarbin Gloria Pharmaceuticals Co., Ltd.
Listing DateJun 23, 2010
Issue Price50.00
Shares Offered35.00M share(s)
FoundedMar 27, 2000
Listed ExchangeSZ Stock Exchange
Legal Representativejin hu
General Managerleifeng guo
Secretaryyueyin liu
Accounting FirmShanghui Accounting Firm (Special General Partnership)
Securities Representativexuelong bai
Legal CounselBeijing Jingxuan Law Firm
Employees59
Phone010-80479607
Office AddressBuilding 28, Ronghui Park, Yuhua Road, Area B, Airport Development Zone, Shunyi District, Beijing
Zip Code101318
Registered AddressNo. 29, Beijing Road, Limin Economic and Technological Development Zone, Hulan District, Harbin City, Heilongjiang Province
Fax010-68002438-607
Emailirm@gloria.cc
Business License230000400002254
BusinessProduction and sale of tablets, capsules, granules, powder injections (all cephalosporins), powder injections (hormones), dry suspensions, small-volume injections (including antineoplastic drugs), freeze-dried powder injections (including antineoplastic drugs, cephalosporins), suppositories, raw materials (Qinlongxin, yanhuning, etomidate, flubiprofen ester), imported drugs are packaged separately (injections (sodium hyaluronate injections); technical consultation, process technology transfer, technology development.

Company Executives

  • Name
  • Position
  • Salary
  • jin hu
  • Chairman, Directors, Chairman of the Strategy Committee, Audit Committee Member
  • --
  • kang zhou
  • Directors, Deputy General Manager
  • 1.86M
  • leifeng guo
  • Directors, General Manager, Head of Finance, Nomination Committee Members, Member of the Remuneration and Assessment Committee, Strategy Committee Member
  • --
  • dongxu wang
  • Directors
  • 1.90M
  • xiaodan zhang
  • Independent Directors, Audit Committee Member, Chairman of the Nomination Committee, Strategy Committee Member, Chairman of the Remuneration and Assessment Committee
  • 200.00K
  • min pan
  • Independent Directors, Chairman of the Audit Committee, Member of the Remuneration and Assessment Committee, Nomination Committee Members
  • 200.00K
  • yueyin liu
  • Board Secretary, Deputy General Manager, Head of Risk Control Center
  • --
  • xuelong bai
  • Securities Affairs Representative
  • --
  • lili shang
  • Shareholder Supervisors
  • --
  • chao zhang
  • Shareholder Supervisors
  • --
  • runbao li
  • Deputy General Manager
  • --
  • xiaohang wang
  • Deputy General Manager
  • --
  • fusheng yang
  • Employee Supervisors
  • --
Heat List
CN
Overall
Symbol
Price
% Chg

No Data